Wound Management Technologies Expands Internationally with Inaugural Order from Mexico

ADDISON, TX / ACCESSWIRE / March 16, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM) (“Company”), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced that Wound Care Innovations (“WCI”), a subsidiary of the Company, received its inaugural order from Mexico, where WCI is registered and signed a distribution agreement with VISECA Desarrollo Inmobiliario SA de CA (“VISECA”), a healthcare distributor in Mexico. CellerateRX(R) received COFEPRIS approval from the Mexico Ministry of Health.

Cesar Camargo, General Manager of VISECA, stated, “We are excited to partner with Wound Care Innovations on the distribution of CellerateRX(R) to the country of Mexico. Diabetes affects almost 50% of the Mexican population and it has cost the government billions to manage the diabetes-related problems. With what we have seen in terms of the clinical data and cost savings, we anticipate the physicians in Mexico introducing the product into their practice at an accelerated rate.”

In addition to Mexico, Wound Care Innovations is also registered and has signed distribution agreements for CellerateRX(R) in Nigeria, Saudi Arabia, South Africa, and Trinidad. WCI also has registrations in process in many additional countries.

Robert Lutz, Jr., Chairman and Chief Executive Officer, commented, “Diabetes and the health risks associated with the disease continue to be on the rise worldwide. The opportunity to enter these international markets further supports the growth trajectory of the Company and allows us to continue to execute on our corporate strategic growth initiatives. We believe that the clinical efficacy of CellerateRX(R), paired with its cost efficiency, fills an unmet need in these countries and we look forward to further expansion as we continue to pursue registration and distribution in other countries.”

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

KCSA Strategic Communications
Todd Fromer / Garth Russell
+ 212-682-6300
Tfromer@kcsa.com / Grussell@kcsa.com

SOURCE: Wound Management Technologies Inc.

ReleaseID: 426879